Getting Back to Normal: Care by Putting Patients First

Head of US Medical Affairs

Interim Head of Oncology Development

Dr. Botwood was recently appointed to lead the US Medical Affairs organization at Bristol Myers Squibb. He is responsible for US Medical’s first-in-class business model, developing a robust pipeline, supporting multiple launches and ensuring medical capabilities are in place to effectively execute on these priorities.

Dr. Botwood recently led the Oncology Clinical Development organization and is the interim Head of Oncology Development, responsible for the development, clinical monitoring, interpretation and analysis of all clinical trials and protocols in late stage development and life cycle management; also responsible for all global clinical development components of regulatory documents. Over the last three years, Nick and his team, working with broad cross functional groups have supported multiple new indications and asset transitions. He joined Bristol Myers Squibb in March 2015 as the OPDIVO/YERVOY Thoracic Development Team lead and led the team to worldwide approvals of OPDIVO in Lung Cancer and Head and Neck Cancer.  

Prior to joining Bristol Myers Squibb, Nick spent 12 years at AstraZeneca in a variety of leadership roles including Medical, Operations, and Clinical Development. He trained as a clinical oncologist at Imperial College and the Hammersmith Hospital, leading a number of early phase clinical trials. He has an Honors Degree from University College London in Philosophy of Science and History of Medicine and is a member of the Royal College of Physicians UK and Faculty of Pharmaceutical Medicine.